MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone
A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...
Future Market Insights8d
Generic Oncology Drug Industry in Europe and MENA Poised for Substantial Growth, Reaching USD 8.2 Billion by 2033 soar at a 2.1% CAGR
A new wave of hope is sweeping across Europe and MENA for millions of cancer patients seeking affordable and effective treatment options. The rise of generic oncology drugs is offering a much-needed ...
Statistisches Bundesamt17d
Short-term indicators Economic and financial data for Germany
For a fuller explanation of the DSBB and the statistical standards to which Germany has committed, please click on DSBB Home Page.
pharmaphorum18d
Sanofi's immunotherapy Libtayo gets FDA approval in first line lung cancer
Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...
pharmaphorum20d
Sanofi, Regeneron prep filings for Libtayo in cervical cancer
Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...
Sky21d
Germany: Europe's largest economy is facing a third consecutive year of recession
The most important European data release was the confirmation from Germany that, during 2024, its economy contracted for the second consecutive year. Europe's largest economy shrank by 0.2% during ...
Associated Press22d
Germany’s economy shrank for the second consecutive year in 2024
Copyright 2025 The Associated Press. All Rights Reserved. Trucks and cars move along on a highway in Frankfurt, Germany, Wednesday, Jan. 15, 2025. (AP Photo/Michael ...
Seeking Alpha22d
Regeneron: Phase III Success In Skin Cancer For Libtayo
Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...
Pharmabiz22d
Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial
Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...
Business Insider22d
Regeneron Buy Rating Supported by Eylea HD Launch, Dupixent Expansion, and Libtayo Success
Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...
The New York Times22d
Germany’s Economy Shrank Last Year. Here’s How Politicians Plan to Revive It.
By Melissa Eddy Germany’s economic output shrank for a second straight year in 2024, data released Wednesday showed. How to revive it has become a central issue as voters prepare to go to the ...